AstraZeneca sells rights to anaesthetics to South Africa’s Aspen

LONDON (Reuters) – AstraZeneca said on Thursday it had agreed to sell the commercialisation rights for its portfolio of anaesthetics outside the United States to South Africa’s Aspen Pharmacare for an initial payment of $520 million.

Leave a Reply

Read the original at Reuters: Business News.